Tài trợ serologically tiêu cực đối với CMV b) Leukoreduction bởi một bộ lọc thế hệ thứ ba hoặc thứ tư (Chương 36) c) đông lạnh - deglycerolized tế bào máu đỏ (Chương 39) d) các sản phẩm máu mà không chứa các tế bào màu trắng khả thi, ví dụ huyết tương đông lạnh hoặc cryoprecipitate | Special Blood Products III Cytomegalovirus 163 Table . Types of CMV low risk blood products a Donations which are serologically negative for CMV b Leukoreduction by a third or fourth generation filter Chapter 36 c Frozen - deglycerolized red blood cells Chapter 39 d Blood products which do not contain viable white cells . frozen plasma or cryoprecipitate 38 Table . Indications for CMV risk reduced blood products a Intrauterine transfusions and low birth weight kg infants b Pregnant females of unknown or CMV seronegative status c Bone marrow transplantation I Allogeneic transplantation of CMV negative stem cell product to a CMV negative recipient both potential candidates and identified recipients . II Autologous transplantation in a CMV negative patient d Solid Organ Transplantation CMV Seronegative candidates e T cell-immunodeficiency state in a CMV seronegative patient . Acquired Immune Deficiency Syndrome Severe Combined Immunodeficiency Disease. generally is between CMV seronegative components and leukoreduced blood. Studies in the last ten years have shown leukoreduced blood to be essentially equivalent to CMV seronegative blood components. CMV transmission has similarities with irradiated blood Chapter 37 in that only cellular blood products transmit CMV and red cells stored for more than 14 days are not known to transmit CMV. Frozen plasma or cryoprecipitate are CMV low risk products and therefore do not need to be either filtered or manufactured from donations which are CMV seronegative. The appropriate patient populations who should receive CMV low risk blood products are shown in Table . All intrauterine transfusions and transfusions to low birth weight infants Kg should be CMV low risk either a seronegative donor or a leukoreduced product is acceptable for this purpose. Pregnant females of unknown CMV status or who are known to be CMV seronegative should receive CMV low risk products. The occurrence of primary CMV infection in .
